TI
GILD icon

TrueMark Investments’s Gilead Sciences GILD Stock Holding History

TrueMark Investments’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,675
Closed -$574K – 214
2025
Q4 		$574K Buy
+4,675
New +$568K 0.11% 139
2025
Q1 		– Sell
-21,717
Closed -$2.01M – 227
2024
Q4 		$2.01M Buy
21,717
+11,513
+113% +$1.04M 0.64% 57
2024
Q3 		$856K Sell
10,204
-10,430
-51% -$796K 0.27% 89
2024
Q2 		$1.42M Buy
+20,634
New +$1.38M 0.48% 76

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

TrueMark Investments's GILD Position: Q1 2026 in Review

TrueMark Investments sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 4,675 shares — an estimated $574K sold.

TrueMark Investments first reported a position in GILD in Q2 2024 and held it in 4 quarters. The position peaked at $2.01M in Q4 2024. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • TrueMark Investments reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • TrueMark Investments sold 4,675 Gilead Sciences shares in Q1 2026, an estimated $574K.
  • TrueMark Investments first reported a position in Gilead Sciences in Q2 2024 and held it in 4 quarters.
  • TrueMark Investments's Gilead Sciences position peaked at $2.01M in Q4 2024.
  • 2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on TrueMark Investments's 13F filing for Q1 2026, filed 20 Apr 2026.